Freedom Investment Management Inc. Has $258,000 Position in Becton, Dickinson and Company $BDX

Freedom Investment Management Inc. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,500 shares of the medical instruments supplier’s stock after purchasing an additional 174 shares during the period. Freedom Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $258,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares in the last quarter. Perigon Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 59.4% in the first quarter. Perigon Wealth Management LLC now owns 2,911 shares of the medical instruments supplier’s stock valued at $667,000 after acquiring an additional 1,085 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 22.2% in the first quarter. Sequoia Financial Advisors LLC now owns 5,879 shares of the medical instruments supplier’s stock valued at $1,347,000 after acquiring an additional 1,069 shares in the last quarter. Finally, Perpetual Ltd acquired a new position in shares of Becton, Dickinson and Company in the first quarter valued at about $201,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on BDX. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Up 0.6%

BDX stock opened at $187.02 on Tuesday. The stock has a market capitalization of $53.61 billion, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 1.45 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a 50-day moving average price of $189.76 and a 200-day moving average price of $183.63.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 1,838 shares of company stock valued at $348,392 over the last three months. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.